Debra L Richardson1. 1. Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK. Electronic address: Debra-richardson@ouhsc.edu.
Abstract
OBJECTIVE: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. DATA SOURCES: PubMed, FDA.gov, ASCO.org. CONCLUSION: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. IMPLICATIONS FOR NURSING PRACTICE: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.
OBJECTIVE: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. DATA SOURCES: PubMed, FDA.gov, ASCO.org. CONCLUSION: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. IMPLICATIONS FOR NURSING PRACTICE: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.
Authors: Ana Paucarmayta; Hannah Taitz; Yovanni Casablanca; Gustavo C Rodriguez; G Larry Maxwell; Kathleen M Darcy; Viqar Syed Journal: Transl Cancer Res Date: 2019-08 Impact factor: 1.241